These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 38866642)
21. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF). Maeder MT; Rickenbacher P; Rickli H; Abbühl H; Gutmann M; Erne P; Vuilliomenet A; Peter M; Pfisterer M; Brunner-La Rocca HP; Eur J Heart Fail; 2013 Oct; 15(10):1148-56. PubMed ID: 23657728 [TBL] [Abstract][Full Text] [Related]
22. Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity. Reddy YNV; Rikhi A; Obokata M; Shah SJ; Lewis GD; AbouEzzedine OF; Dunlay S; McNulty S; Chakraborty H; Stevenson LW; Redfield MM; Borlaug BA Eur J Heart Fail; 2020 Jun; 22(6):1009-1018. PubMed ID: 32150314 [TBL] [Abstract][Full Text] [Related]
23. Are existing and emerging biomarkers associated with cardiorespiratory fitness in patients with chronic heart failure? Fudim M; Kelly JP; Jones AD; AbouEzzeddine OF; Ambrosy AP; Greene SJ; Reddy YNV; Anstrom KJ; Alhanti B; Lewis GD; Hernandez AF; Felker GM Am Heart J; 2020 Feb; 220():97-107. PubMed ID: 31805424 [TBL] [Abstract][Full Text] [Related]
24. Identifying a low-flow phenotype in heart failure with preserved ejection fraction: a secondary analysis of the RELAX trial. Patel KV; Mauricio R; Grodin JL; Ayers C; Fonarow GC; Berry JD; Pandey A ESC Heart Fail; 2019 Aug; 6(4):613-620. PubMed ID: 30993916 [TBL] [Abstract][Full Text] [Related]
25. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial. Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR; JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839 [TBL] [Abstract][Full Text] [Related]
26. The level of NT-proBNP in ambulatory patients with chronic heart failure with preserved ejection fraction of the left ventricle. Kirillova VV; Sokolova LA; Meshchaninov VN; Pershanova VI Ter Arkh; 2018 Sep; 90(9):68-72. PubMed ID: 30701738 [TBL] [Abstract][Full Text] [Related]
27. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Association With Exercise Capacity, Left Ventricular Filling Pressures, Natriuretic Peptides, and Left Atrial Volume. Lam CS; Rienstra M; Tay WT; Liu LC; Hummel YM; van der Meer P; de Boer RA; Van Gelder IC; van Veldhuisen DJ; Voors AA; Hoendermis ES JACC Heart Fail; 2017 Feb; 5(2):92-98. PubMed ID: 28017355 [TBL] [Abstract][Full Text] [Related]
28. Twist/untwist parameters are promising evaluators of myocardial mechanic changes in heart failure patients with preserved ejection fraction. Zhang Y; Li SY; Xie JJ; Wu Y Clin Cardiol; 2020 Jun; 43(6):587-593. PubMed ID: 32212277 [TBL] [Abstract][Full Text] [Related]
29. Obesity and Serial NT-proBNP Levels in Guided Medical Therapy for Heart Failure With Reduced Ejection Fraction: Insights From the GUIDE-IT Trial. Parcha V; Patel N; Kalra R; Suri SS; Arora G; Wang TJ; Arora P J Am Heart Assoc; 2021 Apr; 10(7):e018689. PubMed ID: 33754794 [TBL] [Abstract][Full Text] [Related]
30. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583 [TBL] [Abstract][Full Text] [Related]
31. Uncovering Unrecognized Heart Failure With Preserved Ejection Fraction Among Individuals With Obesity and Dyspnea. Kosyakovsky LB; Liu EE; Wang JK; Myers L; Parekh JK; Knauss H; Lewis GD; Malhotra R; Nayor M; Robbins JM; Gerszten RE; Hamburg NM; McNeill JN; Lau ES; Ho JE Circ Heart Fail; 2024 May; 17(5):e011366. PubMed ID: 38742409 [TBL] [Abstract][Full Text] [Related]
32. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction. Chan MM; Santhanakrishnan R; Chong JP; Chen Z; Tai BC; Liew OW; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong RC; Chai P; Low AF; Richards AM; Lam CS Eur J Heart Fail; 2016 Jan; 18(1):81-8. PubMed ID: 26497848 [TBL] [Abstract][Full Text] [Related]
33. Diagnostic significance of serum galectin-3 levels in heart failure with preserved ejection fraction. Polat V; Bozcali E; Uygun T; Opan S; Karakaya O Acta Cardiol; 2016 Apr; 71(2):191-7. PubMed ID: 27090041 [TBL] [Abstract][Full Text] [Related]
34. Biomarkers for characterization of heart failure - Distinction of heart failure with preserved and reduced ejection fraction. Sinning C; Kempf T; Schwarzl M; Lanfermann S; Ojeda F; Schnabel RB; Zengin E; Wild PS; Lackner KJ; Munzel T; Blankenberg S; Wollert KC; Zeller T; Westermann D Int J Cardiol; 2017 Jan; 227():272-277. PubMed ID: 27838133 [TBL] [Abstract][Full Text] [Related]
35. Interaction of Body Mass Index on the Association Between N-Terminal-Pro-b-Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). Bhatt AS; Cooper LB; Ambrosy AP; Clare RM; Coles A; Joyce E; Krishnamoorthy A; Butler J; Felker GM; Ezekowitz JA; Armstrong PW; Hernandez AF; O'Connor CM; Mentz RJ J Am Heart Assoc; 2018 Feb; 7(3):. PubMed ID: 29431103 [TBL] [Abstract][Full Text] [Related]
36. Renal function, N-terminal Pro-B-Type natriuretic peptide, propeptide big-endothelin and patients with heart failure and preserved ejection fraction. Gergei I; Krämer BK; Scharnagl H; Stojakovic T; März W Peptides; 2019 Jan; 111():112-117. PubMed ID: 29684593 [TBL] [Abstract][Full Text] [Related]
37. Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes. Zabarovskaja S; Hage C; Linde C; Daubert JC; Donal E; Gabrielsen A; Mellbin L; Lund LH Int J Cardiol; 2015; 189():6-11. PubMed ID: 25885866 [TBL] [Abstract][Full Text] [Related]
38. Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study. Jhund PS; Anand IS; Komajda M; Claggett BL; McKelvie RS; Zile MR; Carson PE; McMurray JJ Eur J Heart Fail; 2015 Aug; 17(8):809-17. PubMed ID: 25921853 [TBL] [Abstract][Full Text] [Related]
39. Obesity does not influence the correlation between exercise capacity and serum NT-proBNP levels in chronic heart failure. Ferreira AM; Mendes M; Ventosa A; Aguiar CT; Ferreira J; Figueira JM; Silva JA Int J Cardiol; 2008 Oct; 130(1):103-5. PubMed ID: 17692409 [TBL] [Abstract][Full Text] [Related]
40. Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. Kristensen SL; Jhund PS; Køber L; McKelvie RS; Zile MR; Anand IS; Komajda M; Cleland JGF; Carson PE; McMurray JJV JACC Heart Fail; 2015 Jun; 3(6):478-486. PubMed ID: 26046842 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]